Different Doses of ZED1227 vs. Placebo in NAFLD

PHASE2CompletedINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

June 7, 2023

Study Completion Date

July 5, 2023

Conditions

NAFLDLiver Fibrosis

Interventions

DRUG

ZED1227

ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

DRUG

Placebo

Trial Locations (1)

Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Mainz